|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM122665201 |
| 003 |
DE-627 |
| 005 |
20231222195659.0 |
| 007 |
tu |
| 008 |
231222s2002 xx ||||| 00| ||eng c |
| 028 |
5 |
2 |
|a pubmed24n0409.xml
|
| 035 |
|
|
|a (DE-627)NLM122665201
|
| 035 |
|
|
|a (NLM)12482392
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Burns, James B
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a In vivo activation of myelin oligodendrocyte glycoprotein-specific T cells in healthy control subjects
|
| 264 |
|
1 |
|c 2002
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 15.01.2003
|
| 500 |
|
|
|a Date Revised 06.11.2019
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Autoreactive T cells are present in healthy subjects but are assumed not to induce overt disease due to lack of exposure to autoantigen or because of immune regulation. In EAE, activation of myelin protein-specific T cells is a crucial step in disease induction. In this study, we evaluated whether myelin oligodendrocyte glycoprotein (MOG)-reactive T cells had been activated in vivo using peripheral blood mononuclear cells from neurologically healthy subjects. In vitro assays used either memory, CD45RO(+), or naïve, CD45RA(+) T-cell populations. MOG-reactive T cells were isolated from 7 of 10 subjects. Unexpectedly, a substantial number of MOG-reactive T cells were isolated from the CD45RO(+), memory T-cell subset in 6 subjects. The majority of these T cells generated gamma interferon in excess of IL-4, expressed VLA-4, and produced nerve growth factor. These findings demonstrate that a substantial proportion of MOG-reactive T cells from some subjects have been activated in vivo without resulting in clinical disease
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
4 |
|a Research Support, U.S. Gov't, Non-P.H.S.
|
| 650 |
|
4 |
|a Research Support, U.S. Gov't, P.H.S.
|
| 650 |
|
7 |
|a Autoantigens
|2 NLM
|
| 650 |
|
7 |
|a MOG protein, human
|2 NLM
|
| 650 |
|
7 |
|a Myelin Proteins
|2 NLM
|
| 650 |
|
7 |
|a Myelin-Associated Glycoprotein
|2 NLM
|
| 650 |
|
7 |
|a Myelin-Oligodendrocyte Glycoprotein
|2 NLM
|
| 650 |
|
7 |
|a Leukocyte Common Antigens
|2 NLM
|
| 650 |
|
7 |
|a EC 3.1.3.48
|2 NLM
|
| 700 |
1 |
|
|a Bartholomew, Breck D
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Lobo, Stephen T
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 105(2002), 2 vom: 01. Nov., Seite 185-91
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:105
|g year:2002
|g number:2
|g day:01
|g month:11
|g pages:185-91
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 105
|j 2002
|e 2
|b 01
|c 11
|h 185-91
|